rivaroxaban / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 97 Diseases   239 Trials   239 Trials   14341 News 


«12345678910111213...166167»
  • ||||||||||  rivaroxaban / Generic mfg., prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
    A Case of MOG-AD in an 89-year-old Male (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3340;    
    The patient was diagnosed with MOGAD and started on IV Methylprednisolone followed by a Prednisone taper with improvement. MOGAD should be considered on the differential for thoracic myelopathy, when the clinical features, imaging and CSF findings are suggestive of this diagnosis even in older patients outside the typical age range for this disease.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Journal, Real-world evidence, Real-world:  Real-world experience of direct oral anticoagulant use in a single pediatric center. (Pubmed Central) -  Mar 7, 2024   
    However, this observation may be attributed to patients who had ongoing risk factors, as well as a longer duration of study follow-up. Additional multicentered outcome studies evaluating DOAC use in children are needed to determine long-term recurrence and HMB risks.
  • ||||||||||  Zontivity (vorapaxar) / Merck (MSD)
    Review, Journal:  Thrombin as target for prevention of recurrent events after acute coronary syndromes. (Pubmed Central) -  Mar 4, 2024   
    We explored the evidence supporting thrombin generation in the pathophysiology of recurrent events post-ACS and the role of thrombin as a viable therapeutic target. One specific target is factor XI inhibition, which is involved in thrombin generation, but may also allow for the preservation of normal hemostasis.
  • ||||||||||  rivaroxaban / Generic mfg.
    Preclinical, Journal:  A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban. (Pubmed Central) -  Mar 4, 2024   
    One specific target is factor XI inhibition, which is involved in thrombin generation, but may also allow for the preservation of normal hemostasis. This study showed that the branded and generic rivaroxaban exert an identical in vitro anticoagulant effect across a wide range of concentrations.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Journal:  Development of a Rapid Qualitative Screen for Anticoagulant Presence. (Pubmed Central) -  Mar 4, 2024   
    This study showed that the branded and generic rivaroxaban exert an identical in vitro anticoagulant effect across a wide range of concentrations. Our study demonstrates that commonly available heparin anti-Xa activity and TT assays can be used to qualitatively detect DOACs and fondaparinux and provides a method to establish a qualitative interpretation.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Anticoagulation patterns in haemodialysis patients - how do we anticoagulate in the absence of indications? (ePosters screen 11) -  Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_2408;    
    Even though DOACs are not approved in Europe for HD patients, in this Romanian center, a significant proportion of patients (13.7%) were recommended these anticoagulants, stressing the need for a more predictable and easy way to use anticoagulant agent. Acknowledging multiple comorbidities encountered in HD patients, such as increased hemorrhagic and thrombotic risk, alongside with frequent anemic syndrome, create a great challenge in order to choose a tailored anticoagulant treatment.
  • ||||||||||  rivaroxaban / Generic mfg., ticagrelor / Generic mfg., aspirin / Generic mfg.
    Safety and efficacy of prolonged antithrombotic therapy in high-risk patients followed in a dedicated secondary prevention consultation (ePosters screen 26) -  Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_2017;    
    While patients on rivaroxaban exhibit more CV risk factors associated with multivessel systemic disease, patients on ticagrelor tend to have more isolated CAD, presenting with acute events. Further studies are needed to assess long-term outcomes, nonetheless, this work proves the safety and effectiveness of a tailor-made decision between antithrombotic strategies, according to specific patients
  • ||||||||||  Risk profile of patients in a secondary cardiovascular prevention program: thrombotic versus hemorrhagic (ePosters screen 26) -  Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_2015;    
    Prolonged antithrombotic therapy, guided by careful baseline risk assessment, showed no adverse events after one year. Although long-term effects require further observation, this hospital-based secondary prevention consultation allows the close monitoring of high-risk patients, ensuring safe antithrombotic therapy prolongation based on individual thrombotic and hemorrhagic risk assessments.
  • ||||||||||  apixaban / Generic mfg.
    Generic apixaban: how should we buy it at the hospital level? (ePosters screen 4) -  Mar 4, 2024 - Abstract #HEARTFAILURE2024HEART_FAILURE_1317;    
    Conclusion Oral anticoagulants prescription costs in a hospital with approximately 800 beds is relatively low when compared to the other healthcare total costs. To be able to save at least 10,000
  • ||||||||||  Adakveo (crizanlizumab-tmca) / Novartis, Innohep (tinzaparin) / LEO Pharma
    ROLE OF ANTIPLATELET AND ANTICOAGULANT THERAPY IN VENO-OCCLUSIVE CRISIS (VOC) (Sheraton Ballroom IV-V; Virtual) -  Mar 2, 2024 - Abstract #THSNA2024THSNA_155;    
    Conversely, trials with rivaroxaban and apixaban, which target factor X, have not yielded positive results, potentially attributed to sample size and length of treatment...Potential challenges such as bleeding risks and contraindications (eg stroke history), are important considerations when investigating anticoagulant therapies in SCD. Recognizing that vaso-occlusive episodes are likely to be a problem for many decades in the US and elsewhere in SCD, future research should prioritize larger and well-designed clinical trials and explore the long-term implications of these targeted interventions in shaping the landscape of SCD management.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    DISCOVERING NOVEL PRO-COAGULANT AGENTS FROM SNAKE VENOM (Sheraton Ballroom IV-V; Virtual) -  Mar 2, 2024 - Abstract #THSNA2024THSNA_143;    
    Slounase treatment reverses the anticoagulant effect of FXa inhibitors rivaroxaban and apixaban in vitro and in vivo. Our results demonstrate that slounase is a potential bypassing agent to restore hemostasis in bleeding associated with inherited coagulation disorders and as a rapid reversal agent for anticoagulation by FXa inhibitors to decrease bleeding and blood loss.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    DOAC'S IN THE ELDERLY (Riverwalk AB; Virtual) -  Mar 2, 2024 - Abstract #THSNA2024THSNA_131;    
    Our results demonstrate that slounase is a potential bypassing agent to restore hemostasis in bleeding associated with inherited coagulation disorders and as a rapid reversal agent for anticoagulation by FXa inhibitors to decrease bleeding and blood loss. Types of DOACs Factor Xa Inhibitors :
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    NOVEL POINT-OF-CARE (POC) PLATFORM FOR DIRECT ORAL ANTICOAGULANTS (DOAC) AND VITAMIN K ANTAGONISTS (AVK) TESTING: MICRODOAC AND MICROINR ASSAYS (Riverwalk AB; Virtual) -  Mar 2, 2024 - Abstract #THSNA2024THSNA_112;    
    A novel Point-of-Care platform has been developed to enhance the quality management of patients on oral anticoagulation therapy (DOACs and VKAs) in various clinical environments. This new analyzer provides lab-quality results based on microfluidic technology, enabling real-time patient monitoring across diverse clinical setting with rapid results (<2 minutes), portable design, user-friendly interface, and connectivity for patient traceability.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    INVESTIGATING INTER-ASSAY VARIABILITY BETWEEN DOAC CALIBRATED ANTI-FACTOR XA ASSAYS: A SUBSTUDY OF THE PAUSE TRIAL (On-Demand/Online; Virtual) -  Mar 2, 2024 - Abstract #THSNA2024THSNA_102;    
    Using plasma from patients who had interrupted factor-Xa inhibitor DOAC therapy we were able to demonstrate that anti-Xa levels determined by three of the most common reagent-instrument combinations correlate well with each other, when anti-Xa activity is 30 ng/mL. Although there are statistically significant differences between median anti-Xa levels in the <30 ng/mL group, particularly for rivaroxaban, these differences are small and not clinically significant and result in discrepant classification across the 30 ng/mL threshold in only 7.3% of samples.
  • ||||||||||  rivaroxaban / Generic mfg.
    INFLUENCE OF PHARMACEUTICAL INDUSTRY ON PUBLISHED CLINICAL TRIAL RESULTS (Riverwalk AB; Virtual) -  Mar 2, 2024 - Abstract #THSNA2024THSNA_46;    
    Methods RECORD 4 trial The FDA approved rivaroxaban in July 2011 Results of the four RECORD trials revealed data integrity problems in the RECORD4 trial...Being honest, revealing financial relations to the industry, and the process of professional peer review are recommended. Our message is that honesty is the best policy, asking
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban. (Pubmed Central) -  Mar 2, 2024   
    DOACs can be used in patients with CTP A cirrhosis, and apixaban, dabigatran and edoxaban can also be used in CTP B. It is recommended to avoid rivaroxaban in CTP B and C. There is insufficient evidence to support safe use of other DOACs in CTP C cirrhosis. The sample size was too low to draw any firm conclusions but is seems that MRX PT DOAC might be a useful laboratory test in situations where the effect of Rivaroxaban needs evaluation.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Enrollment change, Trial completion date, Trial termination:  ARIVA: Aspirin (clinicaltrials.gov) -  Mar 1, 2024   
    P2,  N=172, Terminated, 
    Further robust investigations are warranted to confirm our findings. N=316 --> 172 | Trial completion date: Jun 2024 --> Feb 2024 | Suspended --> Terminated; Recommendation by DSMB
  • ||||||||||  rivaroxaban / Generic mfg., lenalidomide / Generic mfg., aspirin / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  RithMM: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (clinicaltrials.gov) -  Feb 28, 2024   
    P2/3,  N=57, Active, not recruiting, 
    N=316 --> 172 | Trial completion date: Jun 2024 --> Feb 2024 | Suspended --> Terminated; Recommendation by DSMB Recruiting --> Active, not recruiting | N=86 --> 57 | Trial completion date: Jul 2026 --> Sep 2024 | Trial primary completion date: Dec 2024 --> Dec 2023
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Primary results of the brazilian registry of atherothrombotic disease (NEAT). (Pubmed Central) -  Feb 25, 2024   
    P=N/A
    The identification of those factors that increase the risk of HF worsening could be helpful in the comprehensive management of this population. Regarding evidence-based therapies (EBTs), 4% were not using any antithrombotic drug and only 1.5% were using vascular dose of rivaroxaban (2.5
  • ||||||||||  Praxbind (idarucizumab) / Boehringer Ingelheim, AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
    Journal:  Direct oral anticoagulants in trauma patients. (Pubmed Central) -  Feb 23, 2024   
    Compared to VKAs, DOACs do not carry a higher bleeding risk. DOAC specific antagonists facilitate the individual bleeding management.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Journal, Surgery:  Effect of direct oral anticoagulants on bleeding during and after cataract surgery. (Pubmed Central) -  Feb 20, 2024   
    Further evaluation of potential pharmacy chain effects on safe use would be of value. Cataract surgery was safely performed while continuing direct oral anticoagulation.